Evidence map›Paper›PMID 35912162›Full record

ArticleComputational and mathematical methods in medicine2022

A New Method for Early Screening of Gastric Cancer (G17 and CA724 Dual-Labeled Time-Resolved Fluorescence Immunoassay).

Chang Liu, Cuicui Chen, Hongrui Lai, Huankun Liang, Shuhai Zhong, Guiling Guo, Lei Wang, Laiqing Li

RetractedOpen access · hybridAbstract readRetracted Publication
In one paragraph

Article in Computational and mathematical methods in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors.

Chang LiuHeilongjiang Academy of Chinese Medicine Sciences, Harbin, 150036, China.ORCID https://orcid.org/0000-0001-8080-3900
Cuicui ChenGuangzhou Youdi Bio-Technology Co., Ltd., Guangzhou 510663, China.ORCID https://orcid.org/0000-0002-6216-0996
Hongrui LaiGuangzhou Youdi Bio-Technology Co., Ltd., Guangzhou 510663, China.ORCID https://orcid.org/0000-0003-0035-6114
Huankun LiangGuangzhou Youdi Bio-Technology Co., Ltd., Guangzhou 510663, China.ORCID https://orcid.org/0000-0001-9680-7375
Shuhai ZhongGuangzhou Youdi Bio-Technology Co., Ltd., Guangzhou 510663, China.ORCID https://orcid.org/0000-0003-1368-6294
Guiling GuoGuangzhou Youdi Bio-Technology Co., Ltd., Guangzhou 510663, China.ORCID https://orcid.org/0000-0002-5343-3016
Lei WangGuangzhou Youdi Bio-Technology Co., Ltd., Guangzhou 510663, China.ORCID https://orcid.org/0000-0002-4689-1211
Laiqing LiGuangzhou Youdi Bio-Technology Co., Ltd., Guangzhou 510663, China.ORCID https://orcid.org/0000-0002-3749-8354

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastric carcinoma (GC) is one of the most common malignancies in the world with the great early screening challenges. The study is aimed at establishing a new detection method for early screening GC using time-resolved fluorescence immunoassay (TRFIA) via quantitative detection of gastrin-17 (G-17) and carbohydrate antigen 724 (CA724) in serum. Time-resolved analyzer measured the fluorescence intensity. The standards of G-17/CA724 were used for drawing the standard curve, which is used to calculate the concentration of G-17 and CA724 in serum sample. The sensitivity for G-17 was 0.54 pg/mL and for CA724 was 0.28 U/mL with a wide-range analyze concentration (0.1-1000) pg/mL or U/mL. The average recoveries ranged from 100.52% to 110.30% for G-17 and 103.02% to 116.00% for CA724. All CVs of the intra- and interassay were below 10% with high specificity. There was a high

Indexed as

Stomach NeoplasmsBiomarkers, TumorEarly Detection of CancerHumansImmunoassayMass ScreeningSensitivity and SpecificityBiomarkers, Tumor

Identifiers

PMID35912162
PMCPMC9328981
OpenAlexW4286009538

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.